The submission is supported by data from the pivotal WU-KONG1 Part B study, which featured in an or...
Fourth Breakthrough Therapy Designation for sunvozertinib in NSCLC with EGFR exon20ins SHANGHAI, O...
Results of subgroup analysis from the pivotal WU-KONG1B study in relapsed or refractory NSCLC with ...
* Golidocitinib is a first-in-class Janus kinase 1 (JAK1) only inhibitor approved for the treatme...
* Anittumor efficacy of sunvozertinib was observed in patients regardless of baseline EGFR exon20i...
Topline results from Dizal's global pivotal phase II WU-KONG1 Part B study of sunvozertinib will be...
SHANGHAI, April 7, 2024 /PRNewswire/ -- Dizal (688192.SH) today announced that the U.S. Food and Dr...
SHANGHAI, Dec. 13, 2023 /PRNewswire/ -- Dizal today announced that the results of a phase 2 pivotal...
SHANGHAI, Dec. 12, 2023 /PRNewswire/ -- Dizal presented compelling data from its robust portfolio o...
* Full analysis of multinational pivotal study results of golidocitinib in relapsed or refractory...
* Sunvozertinib monotherapy demonstrated superior efficacy and excellent safety in patients in th...
SHANGHAI, Sept. 21, 2023 /PRNewswire/ -- Dizal announced today that the China National Medical Prod...
SHANGHAI, Sept. 14, 2023 /PRNewswire/ -- Dizal today announced that the Center for Drug Evaluation ...
SHANGHAI, Sept. 10, 2023 /PRNewswire/ -- Dizal today announced the publication of the Phase I clini...
* Sunvozertinib, a selective EGFR TKI targeting a wide spectrum of EGFR mutations, is the first C...
* A high concordance was observed between tumor tissue-based and plasma circulating tumor DNA (ctD...
SHANGHAI, May 25, 2023 /PRNewswire/ -- Dizal (688192.SH) today announced that data from its oncolog...
Topline Results from Pivotal Studies of Sunvozertinib and Golidocitinib Selected for Oral Presenta...
SHANGHAI, Jan. 10, 2023 /PRNewswire/ -- Dizal (SHEX: 688192) today announced that the Center for Dr...
* The confirmed objective response (cORR), as assessed by blinded independent central review (BIC...